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Abstract
The aggressiveness of pancreatic ductal adenocarcinoma (PDA) is characterized by its high metastatic potential and lack of
effective therapies, which is the result of a lack of understanding of the mechanisms involved in promoting PDA metastases.
We identified Annexin A2 (ANXA2), a member of the Annexin family of calcium-dependent phospholipid binding proteins,
as a new molecule that promotes PDA invasion and metastases. We found ANXA2 to be a PDA-associated antigen
recognized by post-treatment sera of patients who demonstrated prolonged survival following treatment with a PDA-
specific vaccine. Cell surface ANXA2 increases with PDA development and progression. Knockdown of ANXA2 expression by
RNA interference or blocking with anti-ANXA2 antibodies inhibits in vitro invasion of PDA cells. In addition, post-vaccination
patient sera inhibits in vitro invasion of PDA cells, suggesting that therapeutic anti-ANXA2 antibodies are induced by the
vaccine. Furthermore, cell-surface localization of ANXA2 is tyrosine 23 phosphorylation-dependent; and tyrosine 23
phosphorylation is required for PDA invasion. We demonstrated that tyrosine 23 phosphorylation resulting in surface
expression of ANXA2 is required for TGFb-induced, Rho-mediated epithelial-mesenchymal transition (EMT), linking the
cellular function of ANXA2 which was previously shown to be associated with small GTPase-regulated cytoskeletal
rearrangements, to the EMT process in PDA. Finally, using mouse PDA models, we showed that shRNA knock-down of
ANXA2, a mutation at tyrosine 23, or anti-ANXA2 antibodies, inhibit PDA metastases and prolong mouse survival. Thus,
ANXA2 is part of a novel molecular pathway underlying PDA metastases and a new target for development of PDA
therapeutics.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) remains a lethal
cancer with an overall 5-year survival rate of ,5% [1]. Inability
to diagnose early, high metastatic potential, and drug resistance
account for its low survival rate. Although it is well-established
that the pathogenesis of PDAs follows stepwise stages that
display increasing cellular atypia and accumulate clonal
mutations or aberrant expression of oncogenes or tumor
suppressor genes such as K-Ras, p16, p53, and DPC4/SMAD4
[2], drugs that target these molecular abnormalities have not yet
translated into improved clinical responses [3]. The aggressive
nature of PDA is featured by its high incidence of metastases at
the time of initial diagnosis and high incidence of early
metastases following surgical resection. However, little is known
about the molecular mechanisms underlying its invasion and
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19390metastatic processes. A better understanding of these mecha-
nisms is essential for the development of innovative and
improved treatments for PDA.
Cancer immunotherapy treatment approaches are under
development for PDA. We developed an allogeneic, granulocyte-
macrophage colony-stimulating factor (GM-CSF) secreting PDA
vaccine for patients with PDA[4,5,6]. Phase I and II trials
evaluating this vaccine in patients with resected PDA demonstrat-
ed both clinical and immunologic responses[4,5]. This immuno-
therapy approach provided immunized lymphocyte reagents for
identifying novel PDA antigens that are currently being tested as
targets for PDA therapy[7,8]. The potential therapeutic targets
identified so far have also provided important clues for the study of
molecular mechanisms underlying PDA development and metas-
tases. Here we report the utilization of a functional proteomic
approach that identified Annexin A2 (ANXA2) as a new candidate
PDA target of the immune response. In addition, we show that
tyrosine 23 phosphorylation-dependent cell-surface localization of
Annexin A2 is required for epithelial to mesenchymal transition,
invasion, and metastases formation of PDAs.
Results
Identification of ANXA2 as a new candidate PDA tumor-
associated antigen and biomarker
We used immunized sera from two subjects who demonstrated both
evidence of post-vaccination cellular immune responses and prolonged
disease-free survival (DFS) and overall survival (OS) in a phase II study
of a GM-CSF secreting whole cell PDA vaccine [4] to screen whole cell
extracts from the PDA vaccine cell lines which served as the proteome.
Protein extracts were separated by a two-dimensional electrophoresis
(2-DE); and immunoblot analysis was performed to compare antigen
recognition by pre- and post-vaccination sera. Proteins recognized by
post-vaccination sera relative to pre-vaccination sera were identified by
mass spectrometry. ANXA2 was a protein identified on the post-
vaccination sera immunoblots of both patients evaluated. To further
evaluate the prevalence of post vaccination humoral responses to
ANXA2, purified recombinant ANXA2 was used to screen pre-
vaccination and post-vaccination sera from 16 additional patients
treated in this phase II study by both ELISA and western blot (Figure
S1). Vaccine induced anti-ANXA2 antibodies, measured by a
sandwich ELISA, were detected in 6 of 7 patients who demonstrated
a DFS greater than 36 months [4], and only in 1 of the other 9 patients
who did not demonstrate long-term DFS (Table 1). These data
provide the first evidence that ANXA2 is an antibody target of immune
responses against PDA.
ANXA2 is reported to be overexpressed in a variety of cancers
including PDA when compared with normal tissues[9]. Howev-
er, ANXA2 is normally a cytoplasmic and lumenal residing
protein in pancreatic tissue, and previous studies[9] have not
determined whether cell surface ANXA2 expression is a
dominant pattern in PDA tissues. Therefore, we analyzed the
location of ANXA2 expression by immunohistochemistry (IHC)
in the resected tumors from 52 of the 60 patients treated in our
Phase II study for whom specimens were available for staining.
We found that normal pancreatic ductal epithelial cells show
weak cytoplasmic and lumenal staining by IHC, whereas cell-
surface localized ANXA2 increases with progression from PanIN
lesions to invasive PDA (Figure S2). Specifically, 39 (75%) of 52
fresh pancreatic tumor tissue samples tested have increased cell
surface expression of ANXA2 (Figure S2). These data provide
further support that ANXA2 surface expression is associated
with PDA development and as such may serve as an
immunologic target.
Inhibition of ANXA2 suppresses the in vitro invasion of
PDA cells
We next investigated whether the cell surface localization of
ANXA2 plays a biologic role in facilitating PDA invasion. ANXA2
has been reported to bind membrane-associated phospholipids and
Table 1. Correlation between vaccine-induced anti-ANXA2 antibody responses and patients’ disease-free survival.
Patient ID* Disease Status
Disease-Free Survival
Time (Mo)**
Increased Anti-ANXA2 antibody response
(ELISA)
3.009 Disease free .36 +
3.010 Disease free .36 -
3.012 Disease free .36 +
3.016 Disease free .36 +
3.027 Disease free .36 +
3.028 Disease free .36 +
3.031 Disease free .36 +
3.041 Recurrent ,36 -
3.023 Recurrent ,36 -
3.032 Recurrent ,36 -
3.025 Recurrent ,36 +
3.033 Recurrent ,36 -
3.039 Recurrent ,36 -
3.001 Recurrent ,36 -
3.004 Recurrent ,36 -
3.037 Recurrent ,36 -
*Patients underwent surgical resection of PDA and were treated with a GM-CSF secreting PDA vaccine in a phase II clinical trial.
**Disease-free survival is defined as the time from surgery until disease recurrence or until the last follow up on April 21, 2008; Mo, month.
doi:10.1371/journal.pone.0019390.t001
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fibrinolysis, membrane transport, cytoskeleton rearrangement,
angiogenesis, cell adhesion and migration. ANXA2 also functions
as a high-affinity receptor for multiple extracellular ligands that
have been implicated in cancer development, invasion, and
metastases [10,11,12,13]. To directly test whether ANXA2 is
involved in PDA invasion, ANXA2 expression was knocked down
in PDA cells by RNA interference (Figure 1A). Knock-down of
ANXA2 suppressed the in vitro invasion of PDA cells in a Boyden
chamber assay (Figure 1B and Figure S3). The induction of
antibodies against ANXA2 that is observed in vaccinated patients
with prolonged DFS (Table 1) suggests that anti-ANXA2
antibodies may have a direct anti-tumor effect. We therefore tested
both rabbit polyclonal and mouse monoclonal anti-ANXA2
antibodies and found that they can specifically inhibit in vitro
invasion of PDA cells (Figure 1C,D). Moreover, sera from
immunized patients who demonstrated a post-vaccination response
to ANXA2 similarly inhibited in vitro invasion of PDA cells
(Figure 1E). The data presented so far link increasing cell surface
expression of ANXA2 with PDA invasion capability and suggests
that vaccine-induced antibody responses may inhibit this aspect of
PDA progression. However, the mechanism by which ANXA2
mediated PDA invasion occurs has yet to be explored. Interestingly,
the invasive capacity of PDA cells is not correlated with their
proliferative rate suggesting an independent mechanism (Figure
S3). To uncover other regulatory mechanisms that account for the
invasion capacity of PDA cells, we further examined the sub-cellular
localization of ANXA2 in various PDA cell lines by fluorescent
staining with anti-ANXA2 antibodies (Figure S4). ANXA2 is
predominantly localized to the cell membrane in all 8 PDA cell lines
found to have high invasion capacity, whereas ANXA2 is present
predominantly in the cytoplasm of cell lines with low invasion
capacity (Figure S4 and Table S1). This data further support a
role for ANXA2 translocation from the cytosol to the cell surface/
membrane in enhancing PDA cell invasion.
Phosphorylation of ANXA2 at Tyr23 promotes the cell-
surface localization of ANXA2 and the invasion capacity
of PDA cells
ANXA2 is a substrate for Src kinase, which phosphorylates
ANXA2 at Tyr23 both in vivo and in vitro[10,11,12,13], and Tyr23
Figure 1. RNA interference, anti-ANXA2 antibodies, and vaccine-induced sera inhibit ANXA2-mediated PDA invasion in vitro.
A. Western blot analysis showing that ANXA2 siRNA inhibits expression of ANXA2 in a PDA cell line. Whole cell extracts from Panc10.05 treated with
control siRNA and ANXA2 siRNA, respectively, were blotted by rabbit polyclonal anti-ANXA2 antibody (upper panel) and by rabbit polyclonal anti-
GAPDH antibody (lower panel). B. In vitro invasion assay showing that ANXA2 siRNA inhibits the invasion capacity of the 10.05 PDA cell line. Invaded
cells were measured by MTT assays and normalized to total cell numbers. C. Polyclonal anti-ANXA2 antibodies inhibit the invasion capacity of
Panc10.05 cells. D. Mouse anti-ANXA2 monoclonal antibodies (mAb) inhibit the invasion capacity of mouse Panc02 and human Panc10.5 cells. For C
and D, rabbit anti-ANXA2 antibody, rabbit control Ig, mouse anti-ANXA2 mAb (clone: ZO14), or mouse isotype control IgG1 was added into the
culture media at a final concentration of 25 mg/ml throughout the in vitro invasion assays, respectively. E. Only post-vaccination sera from patients
(3.009 and 3.028) who demonstrated anti-ANXA2 antibody responses, but not from patients (3.037 and 3.039) who did not demonstrate anti-ANXA2
antibody responses, inhibit invasion of Panc10.05 cells. Pre- and post- vaccination sera were added to the culture media at a ratio of 1:50. Triplicate
experiments were done for B–E.
doi:10.1371/journal.pone.0019390.g001
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cell scattering and branching morphogenesis[14,15]. ANXA2 is
also reported to be tyrosine-phosphorylated when it localizes to the
cell surface under stress [16]. Since malignant cells often mimic
normal cells that have been subjected to a variety of stress stimuli,
we postulate that ANXA2 is translocated to the cell surface as a
tyrosine-phophorylated protein during tumorigenesis as well. To
test this, we eluted the cell surface fraction of ANXA2 from
Panc10.05 PDA cells, which have cell surface localization of
ANXA2 (Figure S4 and Table S1), and found the cell surface
fraction of the ANXA2 protein is in fact a tyrosine-phosphorylated
protein (Figure 2A). In contrast, ANXA2 could not be eluted
from the cell surface of Panc 3.11 cells, a PDA cell line that
demonstrated cytoplasmic localization of ANXA2 (Figure S4).
To test whether phosphorylation of ANXA2 at Tyr23 is important
for its localization to the PDA cell surface, we generated a panel of
plasmids expressing either wild-type ANXA2 (ANXA2
WT), the
ANXA2 mutant protein (ANXA2
Y23A) in which Tyr23 was altered
to an alanine residue making a non-phosphorylatable mutant, or
the ANXA2 mutant protein (ANXA2
Y23E) in which Tyr23 was
Figure 2. Tyr23 phosphorylation-dependent membrane/cell-surface localization of ANXA2 is required for in vitro invasion of PDA
cells. A. Panc10.05 and Panc3.11 cells were either incubated with EGTA containing buffer or EGTA-free buffer. Two different elutions from two
different PDA cell lines, as indicated, were immunoprecipitated by anti-ANXA2 antibodies (lanes 1–4) or anti-phosphotyrosine (anti-pTyr) antibodies
(lanes 9–12). After elution, the two PDA cell lines were lysed and the lysates were immunoprecipated by anti-pTyr antibodies (lanes 5–8). B. GFP-
tagged ANXA2 in Panc10.05 cells. Upper panels: GFP signals; lower panels: overlapped images of GFP signals and DAPI staining of nuclei. C. FLAG-
tagged ANXA2 expression in Panc10.05 cells transfected with the pcDNA-based plasmid vector alone (lanes 1,5,9,13), the plasmid carrying ANXA2
WT-
FLAG (lanes 2,6,10,14), the plasmid carrying ANXA2
Y23A-FLAG (lanes 3,7,11,15), or the plasmid carrying ANXA2
Y23E-FLAG (lanes 4,8,12,16). Whole cell
extracts (WCE) (lanes 1–4), cell membrane fractions (lanes 5–8, 13–16), or cytoplasmic fractions (lanes 9–12) were isolated by biochemical
fractionation from the Panc10.05 PDA cells, respectively, and immunoprecipitated using either anti-FLAG M2 antibodies (lanes 1–12) or anti-
phosphotyrosine antibodies (anti-pTyr) (lanes 13–16). The immunoprecipitates were blotted using anti-FLAG M2 antibodies. D. In vitro invasion of
Panc10.05 cells. E. In vitro invasion of Panc3.11 cells. For both D and E, cells were transfected with the empty pcDNA-based plasmid vector (lanes 1,2),
the plasmid carrying ANXA2
WT-FLAG (lane 3), the plasmid carrying ANXA2
Y23A-FLAG (lane 4), or the plasmid carrying ANXA2
Y23E-FLAG (lane 5). Lane 1
was also cotransfected with the scramble siRNA control. Lanes 2–5 were also cotransfected with ANXA2 siRNA duplex. Results of duplicate
experiments are shown.
doi:10.1371/journal.pone.0019390.g002
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phosphorylation. When Panc10.05 cells were transfected with
these plasmids expressing ANXA2 tagged by GFP [17],
ANXA2
WT-GFP and ANXA2
Y23E-GFP localized predominantly
to the cell surface of PDA cells. In contrast, ANXA2
Y23A-GFP
localized to the cytoplasm (Figure 2B). These results were further
confirmed by using a lentivirus to constitutively express
ANXA2
WT, ANXA2
Y23A, or ANXA2
Y23E in the PDA cells
(Figure S4). Taken together, these data demonstrate that
phosphorylation at Tyr23 results in the localization of ANXA2
at the cell surface.
To determine whether the change in ANXA2 localization that
occurs as a result of Tyr23 phosphorylation affects the invasion
capacity of PDA cells, a set of plasmids that express exogenous
FLAG-tagged ANXA2 including ANXA2
WT-FLAG, AN-
XA2
Y23A-FLAG, and ANXA2
Y23E-FLAG were developed. These
vectors are RNA interference resistant because of silent mutations
within the siRNA target site. Panc10.05 PDA cells transfected with
these plasmids were fractionated into cytoplasmic and cell
membrane fractions (Figure S4). We first confirmed that only
ANXA2
WT-FLAG and ANXA2
Y23E-FLAG, but not AN-
XA2
Y23A-FLAG, localize to the cell membrane fraction
(Figure 2C). As expected, ANXA2
WT-FLAG protein is tyrosine
phosphorylated in the cell membrane fraction. Next, we found
that co-transfection of the pcDNA plasmid expressing ANXA2
WT-
FLAG or ANXA2
Y23E-FLAG, but not ANXA2
Y23A-FLAG, with
the siRNA (to inhibit endogenous ANXA2), reversed siRNA-
mediated inhibition of invasion of Panc10.05 cells (Figure 2D).
However, in cells with low invasion capacity and only cytoplasmic
localization of ANXA2, such as Panc3.11 (Table S1), co-
transfection with ANXA2
Y23E-FLAG bypasses the phosphoryla-
tion regulatory mechanism by mimicking constitutive phosphor-
ylation and promotes the invasion of Panc3.11 cells (Figure 2E).
These data suggest that Tyr23 phosphorylated ANXA2 confers
PDA invasion capacity.
ANXA2 contributes to the Epithelial-Mesenchymal
Transition of PDA cells
Phosphorylated ANXA2 plays a role in cell scattering in normal
morphogenesis processes[14,15]. Our data so far support a role for
phosphorylated ANXA2 in PDA invasion. The epithelial to
mesenchymal transition (EMT) regulates the normal morphogenic
process during embryonic development and tissue restructuring,
and the initial steps of invasion and metastases are suggested to
mimic EMT[18]. Therefore, we sought to determine whether
ANXA2 is required for the EMT in PDA cells. EMT is
characterized by the suppression of the transcription of epithelial
markers such as E-cadherin and induction of mesenchymal
markers such as slug and vimentin. ANXA2 has been reported
to mediate TGFb-activated EMT during the process of cardiac
valve development [19]. In addition, TGFb is reported to induce
EMT in cultured PDA cells [20,21]. To examine whether ANXA2
has a direct role in the EMT process of invading PDA cells, a
lentiviral vector containing ANXA2 shRNA was used to achieve
long-term suppression of ANXA2 in PDA cells (Figure S3). Real-
time PCR analysis showed that E-cadherin was suppressed,
whereas slug and vimentin were induced during TGFb-induced
EMT in Panc10.05 cells with control shRNA, but not in those
infected with ANXA2 shRNA (Figure 3A). In addition, E-cadherin
protein expression was suppressed in TGFb-treated cells with
control shRNA, but remained unchanged in TGFb-treated cells
that also expressed ANXA2 shRNA (Figure 3B,C). As predicted,
PDA cells without ANXA2 shRNA lose their cell-cell adhesion
phenotype and scatter around the culture slip following TGFb
treatment, reminiscent of an EMT pattern (Figure 3B). Although
ANXA2 has not yet been shown to be involved in SMAD4-
mediated EMT, it has been shown to be involved in Rho (small
GTPases)-mediated cell detachment, a trait of EMT [15].
Therefore, we also evaluated whether Rho mediates ANXA2-
associated EMT in PDA and found that Rho activation is not
detected in PDA cells with shRNA inhibition of ANXA2 following
TGFb treatment (Figure 3C). These results demonstrate that loss
of ANXA2 expression leads to loss of TGFb-Rho-mediated EMT
in PDA cells.
We next examined whether Tyr23 phosphorylation is important
for ANXA2-mediated EMT in PDA cells. We observed that the
endogenous ANXA2 no longer localizes to the cell surface in the
cells expressing the tyrosine site loss variant ANXA2
Y23A (Figure
S4). In addition, transfection with ANXA2
Y23A-FLAG inhibits the
invasion of Panc10.05 cells (Figure S4), suggesting that
ANXA2
Y23A has a dominant negative effect. Consistent with
published data [22], we found that ANXA2
Y23A can still bind to its
partner S100A10/p11 [23] in the cytosol, but not in the cell
membrane (Figure S5). Therefore, overexpressed, cytoplasmic-
localized ANXA2
Y23A may sequester all of the S100A10/p11 in
the cytosol, thereby conferring a dominant negative effect.
Therefore, taking advantage of the dominant negative effect of
ANXA2
Y23A, and employing this ANXA2
Y23A mutant, we further
demonstrated that EMT is induced by TGFb in cells expressing
ANXA2
WT, but not in cells expressing ANXA2
Y23A (Figure 3D).
Thus, these data further demonstrate that the Tyr23 phosphor-
ylation of ANXA2 promotes the EMT of PDA cells and is one
conceivable mechanism by which ANXA2 localizes to the PDA
cell membrane and confers the potential for PDA cells to invade.
Expression and tyrosine phosphorylation of ANXA2 are
required for PDA metastases formation in vivo
Local invasion by tumor cells is a known step in the process of
metastasis. Our data demonstrate that ANXA2 facilitates invasion
of PDA cells in vitro. We therefore employed a transplantable
murine pancreatic cancer model of metastases (Figure S6)t o
evaluate the role of ANXA2 expression, phosphorylation, and cell
surface localization in the PDA metastasis process in vivo. In this
model, 100% of the mice die with liver metastases at approxi-
mately 4-6 weeks (Figure 4A) after splenic injection of 2610
6
Panc02 murine PDA cells. Panc02 cells infected with a GFP
expressing lentivirus carrying shRNA specific for ANXA2 knock-
down or control shRNA were sorted for GFP-positive cells by
FACS. After confirming the knockdown of ANXA2 expression
(Figure S3), 2610
6 cells were injected into the splenic bed prior to
performing a hemisplenectomy, and mice were monitored for
survival. Mice injected with Panc02 cells expressing the ANXA2
shRNA survived significantly longer than mice injected with
Panc02 cells expressing control shRNA (p,0.0001) (Figure 4B).
Necropsy was performed on all mice that died, as well as those that
still survived to day 90 following tumor implantation. Macroscopic
inspection showed that 17/17 mice in the control group, but no
mice (0/17) in the ANXA2 shRNA group developed liver macro-
metastases (Figure 4C). Additional pathologic analyses indicated
that mice in the ANXA2 shRNA group died due to tumor formed
at the splenic bed (local regional tumor growth) (Figure S7). To
confirm that PDA cells carrying ANXA2 shRNA are not able to
seed the liver, 1610
6 Panc02 cells labeled with Qtracker 565 were
injected at the splenic bed. Five days later, frozen sections of liver
were examined under fluorescent microscope for Qtracker 565-
labeled cells (Figure 4D). Significantly fewer Qtracker 565-
positive cells are seen in the livers of ANXA2 shRNA mice when
compared with the control shRNA group (p,0.0001) (Figure 4E).
Targeting Pancreatic Cancer Metastases via ANXA2
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mammals and its phosphorylation can be induced in non-human
mammalian cells [14,15,24]. Thus, the hemisplenectomy model was
again employed to examine whether Tyr23 phosphorylation of
ANXA2 is required for ANXA2-mediated murine PDA metastases.
Mice injected with Panc02 cells stably expressing exogenous
ANXA2
Y23A survived significantly longer than mice injected with
Panc02 cells stably expressing exogenous ANXA2
WT (p=0.001)
(Figure 4F). All 12 mice in the control group whereas 0/12 mice in
theANXA2
Y23Agroupdevelopedlivermacro-metastases(Figure4G).
We also used a previously established orthotopic model in which
PDAs metastasize to the peritoneum [25] to confirm that ANXA2
can initiate metastasis from a primary tumor in addition to
facilitating the seeding of PDA metastases in the liver. This study
confirmed that ANXA2 knockdown does not affect the growth of
primary PDAs significantly (Figure S8). All mice in the control
group developed large peritoneal macro-metastases. In contrast,
most mice in the ANXA2 shRNA group did not develop macro-
metastases. In addition, the mean size of metastatic lesions that
formed in ANXA2 shRNA mice, typically manifesting as micro-
metastatic foci, was significantly smaller (P=0.0012) than the
control mice (Figure S8). IHC analysis of cell surface ANXA2
demonstrated that these micro-metastatic foci were formed by cells
that still expressed ANXA2 due to incomplete knockdown by
ANXA2 shRNA (Figure S8). Taken together, our data provide
strong evidence that Tyr23 phophorylated and cell surface
expressed ANXA2 facilitates the metastatic process, and supports
ANXA2 as a novel target for PDA therapy development.
Figure 3. ANXA2 expression and Tyr23 phosphorylation are required for the EMT process in PDA cells. A. Quantitative real-time PCR
analysis of E-cadherin, slug, and vimentin mRNA expression in Panc10.05 PDA cells with and without knockdown of ANXA2 by shRNA. The relative
ratios of mRNA expression with TGFb1 treatment versus without TGFb1 treatment are shown. The data were normalized with b-actin expression.
B. The same pair of PDA cells employed in panel a were treated with TGFb1 for 0, 36, or 72 hours, respectively, and then harvested for
immunostaining with anti-E-cadherin antibodies and PE-conjugated secondary antibodies. DAPI was used to stain the nuclei. C. The same pair of PDA
cells employed in panel A were treated with TGFb1 for 0, 36, or 72 hours, respectively, and then harvested. A fraction of cell extract was used for
western blot analysis and was stained with anti-E-caherin, anti-RhoA,B,C, or anti-b-actin antibodies as the internal control, respectively. The remaining
cell extract underwent a pull down assay through an affinity column that specifically binds activated, GTP-bound forms of Rho. This was followed by
western blot analysis with anti-Rho antibodies. Note that anti-Rho antibodies recognize Rho A, B and C, whose molecular weights are slightly
different, resulting in two bands on the gel. Control designates the cells with control shRNA; ANXA2 shRNA designates the cells with ANXA2 shRNA. D.
Quantitative real-time PCR analysis of E-cadherin, slug, and vimentin mRNA expression in a pair of Panc10.05 PDA cell lines infected with lentivirus
expressing wild-type ANXA2 (ANXA2-WT) or Y23A mutated ANXA2 (ANXA2-Y23A), respectively. The relative ratios of mRNA expression with TGFb1
treatment (indicated with +) versus without TGFb1 treatment (indicated with -) are shown. The data were normalized with b-actin expression.
doi:10.1371/journal.pone.0019390.g003
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and prolong survival in a mouse model of PDA
Next, we evaluated whether an inhibitory ANXA2-targeted
monoclonal antibody can suppress Panc02 hepatic metastases
using the above described liver metastases forming mouse model.
Specifically, Panc02 injected mice were treated twice weekly with
a mouse monoclonal anti-ANXA2 antibody (shown to inhibit
Panc02 invasion in vitro in Figure 1) until death. All mice (10/10)
in the control IgG group whereas only 1/9 mice in the ANXA2
antibody group developed liver macro-metastases (Figure 5A).
Furthermore, mice treated with the anti-ANXA2 antibody
survived significantly longer than mice treated with isotype control
IgG (p=0.02). Similar to the mice receiving ANXA2 shRNA, mice
in the ANXA2 antibody group died due to tumor progression at
the splenic bed, suggesting this anti-ANXA2 antibody therapy
does not inhibit the growth of primary PDAs. Predictably, mice
implanted with Qtracker 565-labeled Panc02 cells and treated
with a single intraperitoneal injection of anti-ANXA2 antibody
were found to have significantly (p,0.0001) fewer Qtracker 565-
positive cells in their livers as compared with mice given the
control mAb (Figure 5B,C). These data further support ANXA2
as a target for therapeutic intervention of metastases.
Discussion
ANXA2 was brought to our attention as a target of vaccine
induced immune responses identified on a proteomic screen of
PDA proteins using immunized sera from patients who demon-
strated prolonged DFS. A previously published study links
ANXA2 overexpression in pancreatic cancer tissue with rapid
recurrence after gemcitabine adjuvant chemotherapy in postop-
erative patients [26]. In this study, we demonstrate three new
findings that elucidate the role of ANXA2 in PDA invasion and
metastases. First, localization of ANXA2 expression on the cell
surface is required for PDA invasion in vitro and metastases
formation in vivo. Second, Tyr23-phosphorylation is required for
localization of ANXA2 on the PDA cell surface and subsequent
PDA invasion and metastases formation. Importantly, knockdown
of ANXA2 or inhibition with ANXA2 antibody therapy inhibits
the metastatic process. Third, loss of ANXA2 expression or
phosphorylation at Tyr23 leads to loss of TGFb-Rho-mediated
EMT in PDA cells. Taken together, these findings identify a new
role for phosphorylated ANXA2 in mediating PDA cell invasion
via Rho-regulated EMT and facilitating PDA metastases.
Our study shows for the first time that cell surface localization of
ANXA2, mediated by Tyr23 phosphorylation, enhances PDA cell
invasion in vitro and PDA metastases to liver in vivo. Relevant to our
findings, a recent report showed that knockdown of ANXA2 in a
PDA cell line inhibits cell migration in vitro [27]. We also evaluated a
panel of PDA tumor cell lines and 52 fresh tissue specimens and
showed the frequent expression of cell surface ANXA2 in primary
PDAs, which further supports a role for ANXA2 in PDA
progression. Another report demonstrated that the reduction in
cell surface ANXA2 expression in response to changes in interferon
gamma levels leads to reduced prostate cancer cell invasion[28],
suggesting that the cell surface translocation of ANXA2 may be an
important cellular process for multiple types of cancers[10].
We also show that ANXA2 phosphorylation is required for
TGFb-induced and Rho-mediated EMT phenotypes of PDA cells.
A previous study showed that loss of Smad4 expression in PDA
can lead to the aberrant activation of STAT3, which may
contribute to the switch in function of TGFb from a tumor-
suppressive to a tumor-promoting EMT pathway in PDA [20].
Currently, knowledge of the EMT process in cancer development
is largely limited to its characteristic transcription circuit. It is still
unknown how cancer cells functionally undergo cytoskeletal
rearrangement to exhibit mesenchymal features, interact with
extracellular matrix, and migrate to distant locations when the
EMT process is initiated. One of the cellular functions of ANXA2
is its involvement in cytoskeletal rearrangement, which is thought
to be mediated by its tyrosine phosphorylation and its interaction
with small GTPases [14,15]. Thus, our data, linking ANXA2 and
EMT in PDA, provide a new pathway that may regulate the EMT
process that occurs in cancer invasion and metastases.
However, it is still not clear which tyrosine kinases phosphor-
ylate ANXA2 in PDA. A number of tyrosine kinases including Src,
insulin receptor, and insulin-like growth factor (IGF)-1 receptor
have previously been implicated in regulating the cellular function
and cell surface translocation of ANXA2 in normal morphogenesis
processes[14,15,24]. Further investigation of these tyrosine kinases
as mediators of ANXA2 phosphorylation in PDA is therefore
warranted to further delineate the mechanism by which ANXA2
becomes phosphorylated in PDA. In addition, inhibitors of Src
and IGF-1 receptor are under clinical development for the
treatment of various cancers including PDA [29]. Therefore,
ANXA2 phosphorylation or its cell surface translocation may also
serve as a biomarker for assessing treatment response to these
agents. Importantly, blocking ANXA2 by anti-ANXA2 antibodies
can inhibit PDA invasion and metastases, suggesting that ANXA2
and its associated pathways are viable therapeutic targets.
We have used two mouse models of PDA that have provided
complementary data supporting a role for ANXA2 in PDA
progression and metastases formation in vivo. Data employing the
PDA orthotopic model suggests that ANXA2 confers PDA cells
with the invasion and metastasis potential when the PDA cells
originate from the primary tumor. Data from the liver metastasis
Figure 4. shRNA-knockdown of ANXA2 or a mutation at Tyr23 inhibits PDA metastases and prolongs mouse survival. A. Livers from
representative mice receiving intrasplenic injections of mouse PDA cells infected with a lentivirus carrying either control shRNA or ANXA2 shRNA.
B. Kaplan-Meier curves comparing the survival of mice receiving Panc02 cells carrying either control shRNA or ANXA2 shRNA. A log-rank analysis on
Day 90 showed that inhibition of ANXA2 expression with shRNA significantly prolonged survival (p,0.0001). C. Summary of the number of mice
developing metastases in both control and ANXA2 shRNA groups under macroscopic inspection. None of the mice in the ANXA2 shRNA group formed
liver macro-metastases. D. Shown are representative frozen sections of mouse liver imaged under fluorescent microscope assessing Qtracker565-
positive cells and DAPI-stained nuclei. Panc02 cells labeled with Qtracker565 (Invitrogen) were injected into the mouse splenic bed followed by
hemisplenectomy. Three mice in each group were injected with either Panc02 carrying the control shRNA or Panc02 carrying the ANXA2 shRNA. Five
days later, mice were euthanized and 10 frozen sections that cross each liver were stained with DAPI for nuclei and then examined under fluorescent
microscope. In each frozen section, five 20x fields were randomly chosen to score the numbers of Qtracker565-positive cells. E. The sum of five fields
of each section was considered to be one individual data set and a comparison was made between the control shRNA and the ANXA2 shRNA
expressing PDA tumor cells. The result shows that significantly fewer Qtracker565–positive cells were found in the livers from the ANXA2 shRNA
group as compared with the control shRNA group (p,0.0001). F. Kaplan-Meier curves comparing the survival of mice receiving Panc02 cells
expressing either ANXA2-WT or ANXA2-Y23A. A log-rank analysis showed that expression of the Tyr23 phosphorylation-deficient mutant of ANXA2
significantly prolonged survival (p=0.001). G. Summary of the number of mice developing metastases in both ANXA2-WT and ANXA2-Y23A groups.
None of the mice in the ANXA2-Y23A group formed liver macro-metastases.
doi:10.1371/journal.pone.0019390.g004
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formation once the PDA cells gain access to the blood supply
supporting a metastastic site. Thus, ANXA2 appears to be
important for the initial invasion process and for the survival of
PDA cells at their metastatic destination. Accumulated evidence
has supported the ‘‘seed-and-soil’’ hypothesis that the metastatic
‘‘seeds’’ of a given cancer only take root and grow in certain
organs with a welcoming microenvironment or ‘‘soil’’ [30]. Our
data support this hypothesis and suggest that ANXA2 facilitates
PDA cell invasion and motility locally, but also provides an
important signaling pathway linking the PDA cell to the growth
signals in the new metastatic environment (the ‘‘soil’’).
Figure 5. Anti-ANXA2 antibodies inhibit PDA metastases and prolong mouse survival. A. Summary of the number of mice developing
metastases in both isotype control IgG1 and anti-ANXA2 Ab groups. Only one of the mice in the anti-ANXA2 Ab group formed liver macro-
metastases. Mice in the anti-ANXA2 Ab group survived significantly longer than mice in the control IgG group (p=0.02). B. Shown are representative
frozen sections of mouse liver (4 mice/group studied) imaged under a fluorescent microscope for Qtracker565-positive cells and for DAPI-stained
nuclei as described in Figure 4D–E. C. The sum of five 20X fields of each section was considered as one individual data set and was analyzed in the
statistical comparison between the isotype control IgG1 and the anti-ANXA2 antibody group. The result shows that significantly fewer Qtracker565–
positive cells were found in the livers of mice treated with the anti-ANXA2 antibody as compared with the control IgG1 antibody (p,0.0001).
doi:10.1371/journal.pone.0019390.g005
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ANXA2 as a mediator of PDA invasion and metastases.
Additional studies are needed to further elucidate the mechanisms
by which ANXA2 interacts with PDA stroma at both the primary
and metastatic tumor sites to accomplish these processes.
Importantly, this study demonstrated that blocking ANXA2 by
anti-ANXA2 antibodies can inhibit PDA metastases, providing the
rationale for developing therapeutic agents that target ANXA2.
Materials and Methods
Cell lines and tissue culture
The human pancreatic ductal adenocarcinoma (PDA) cell lines
were previously described [31,32]. The human fibroblast cell line
was established from human PDA paracancerous tissues. All
human PDA cell lines were maintained in RPMI1640 media
supplemented with 10% fetal bovine serum (FBS) in a humidified
incubator at 37uC and 5% CO2. The mouse Panc02 cells were
maintained in DMEM media supplemented with 10% FBS in a
humidified incubator at 37uC and 10% CO2. When indicated,
TGFb1 (R&D Systems) was added in the culture medium at a final
concentration of 400 pM. Cells were treated with TGFb1 for
48 hours before harvest unless otherwise noted. The Panc02 cell
line is an established chemical carcinogen induced mouse PDA cell
line that originated from the C57Bl/6 mice [33].
Antibodies
The rabbit polyclonal anti-ANXA2 antibody (H50), mouse
monoclonal anti-ANXA2 antibody (clone: ZO14), mouse mono-
clonal anti-p11 antibody, and the mouse monoclonal anti-E-
cadherin antibody were obtained from Santa Cruz Biotechno-
logy, Invitrogen, BD Transduction, and Zymed Laboratories,
respectively.
Human serum
Human sera and pancreatic tumor tissue samples were obtained
from patients enrolled in a phase II study of an allogeneic GM-
CSF secreting whole cell PDA vaccine. Written informed consent
was obtained in compliance with the Johns Hopkins Medical
Institution Institutional Review Board (IRB)-approved J9988
protocol with approval number #00-01-13-02 [4]. Serum was
collected and stored according to standard procedures.
Enzyme-Linked Immunosorbent Assay (ELISA)
A previously published ELISA assay was used to detect anti-
ANXA2 antibody responses in patients [34]. The calibration curve
was generated with the post-vaccination sera from patient 3.009.
DNA cloning and plasmid constructions
The full-length human ANXA2 cDNA was obtained by reverse
transcription of total RNA purified from Panc10.05 cells, followed
by high-fidelity PCR amplification with ANXA2 primers. The non-
complementary region of the reverse primer also contained the
FLAG tag sequence. The resultant PCR product of ANXA2 cDNA
was then cloned into the pCR vector (Invitrogen) and was
sequenced to confirm no introduction of missense or nonsense
mutations. The ANXA2 cDNA fragment with a C-terminal FLAG
tag was further subcloned into the lentiviral vector (LV). In this
lentivirus, ANXA2 is expressed under the control of the EF-1a
promoter. For the co-transfection of both plasmids and siRNA, the
resultant PCR product of ANXA2 cDNA with a C-terminal FLAG
tag was cloned into the pcDNA3.3 vector (Invitrogen) directly.
Y23A and Y23E mutations were created by site-directed
mutagenesis according to the manufacturer’s manual (Stratagene).
Plasmid transfection, lentiviral infection, and RNA
interference
For plasmid transfection and RNA interference, cells were
seeded in multiple 6-well plates to 80% confluence. For each well,
2 mg of pcDNA-based plasmid and/or 40 pmol siRNA duplex,
were transfected with lipofectamine 2000 in serum-containing
medium according to the manufacturer’s manual (Invitrogen). For
protein expression analysis, cells were harvested at 48 hours. The
ANXA2 siRNA was synthesized by Ambion, Inc.; the scramble
siRNA was purchased from Ambion.
To produce lentivirus expressing ANXA2, the plasmid with
lentiviral constructs was co-transfected with packaging plasmids
into 293T cells as previously described [35]. Lentivirus superna-
tant was collected at 48 hours. For infection, cells were seeded in
multiple 6–well plates to 80% confluence. For each well, 2 ml
lentivirus supernatant was added and incubated for 48 hours
before cells were harvested.
The lentivirus expressing human ANXA2 hairpin shRNA was
obtained from Open Biosystems. Lentivirus was produced
according to the manufacturer’s manual. For infection of
Panc10.05 cells, 6 ml of viral supernatant was added to adherent
cells plated in each 75 cm flask and incubated for 48 hours. Cells
from two flasks were sorted by GFP in a FACS cell sorter at 72–
96 hours after infection. The cells infected with lentivirus
expressing GFP alone were sorted. Total RNA was immediately
extracted after cell sorting. The lentivirus expressing mouse
ANXA2 hairpin shRNA was obtained from GeneCopoeia.
Cell invasion assays
Cell invasion assays were carried out using 96-well Transwell
plates with 8-mm pores and reagents in the Cultrex BME Cell
Invasion Assay system according to the manufacturer’s manual
with modification (R&D Systems). For all invasion experiments,
0.5xBME (Basement Membrane Extract) was used to coat the top
well and 10% serum containing media was added to the bottom
well. To score the cells across the transwell, MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
were used as previously described [36]. Relative MTT units
representing invasion capacity were measured and normalized by
total cell numbers. To assess the spontaneous leakage of cells
through the BME-coated transwell, invasion specific controls were
also performed by adding serum-free media in the bottom wells.
To exclude the effect of such leakage, relative MTT units in the
invasion experiments were adjusted by subtracting the MTT
values of leaked cells in matched invasion specific controls.
PDA cells were plated at 1610
4 cells per well in triplicate. PDA
cells were transfected with either ANXA2-targeted siRNA or
control siRNA prior to plating. Invasion was measured at 48 hours
following plating using an MTT readout system.
Fluorescent immunostaining
Panc10.05 cells were grown on cover slips to 90% confluence
and were fixed in 4% paraformaldehyde for 15 min. Cover slips
were then treated with PBS containing 0.1% Triton X-100 for 5
minutes followed by washing with PBS. After, cover slips were
blocked with 10% normal goat sera in PBS for 1 hour and were
then incubated with rabbit anti-ANXA2 antibodies or mouse anti-
E-cadherin mAb at a 1:100 dilution in 10% normal goat sera
overnight at 4uC. Following a PBS wash, they were further
incubated with FITC-conjugated goat anti-rabbit IgG or PE-
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology) at a
1:200 dilution in 10% normal goat sera at room temperature for
1 hour. They were subsequently washed with PBS containing
Targeting Pancreatic Cancer Metastases via ANXA2
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e193900.5% NP-40. Cover slips were mounted in a medium containing
DAPI (49,6-diamidino-2-phenylindole) (Vector Labs) and exam-
ined by a fluorescent microscope.
Immunohistochemistry (IHC)
IHC staining for both human and mouse ANXA2 was
performed using a standard protocol on an automated stainer
from Leica Microsystems. After deparaffinization and hydration of
tissue, heat induced antigen retrieval was performed with EDTA
buffer (pH 9.0) for 20 minutes. Incubation with the H50 rabbit
anti-AnxA2 antibody (Santa Cruz Biotechnology) at a 1:100
dilution was followed by secondary antibody incubation from the
bond polymer refine detection kit (Leica Microsystems). The
reaction was developed using substrate 3,39-Diamino-benzidine
hydrochloride (DAB). All slides were counterstained with hema-
toxylin. Each area of PDA cells on the entire slide was scored from
0t o3 + by two clinical pathologists (P.I. and R.A.) independently.
Scores of 0 to 3+ measure the different intensities of cell-surface
staining of AnxA2, with a score of 0 representing no staining and a
score of 3+ representing the strongest staining. The percentage of
PDA cells at each score level was estimated. The average score of
cell-surface AnxA2 expression was calculated as follows:
Average Score ~ 0|a%z 1|b% z 2|c% z 3|d%
(a%, b%, c%, and d% are the percentages of PDA cells with score
0 to 3, respectively.)
Whole cell extract and cell fractionation
PDA whole cell extracts were obtained as previously described
[37]. In brief, cell pellets were resuspended in Lysis 250 buffer
followed by a freeze and thaw process that was performed 3 times.
The cell lysate was spun at 15,000 rpm for 10 minutes and
supernatant was removed. The protocols to separate membrane
and cytoplasmic fractions were adapted from those previously
published [38]. EGTA (Ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid) elution of cell surface AnxA2 followed a
previously established procedure [16].
Immunoprecipitation and immunoblot analysis
Anti-phosphotyrosine antibody conjugated sepharose (P-Tyr-
100, Cell Signaling Technology) was used to immunoprecipate
tyrosine-phosphorylated proteins. Anti-AnxA2 antibodies were
first conjugated to sepharose beads according to the manufactur-
er’s manual (Pierce) prior to being used for immunoprecipitation.
Anti-FLAG M2 antibodies-conjugated beads were obtained from
Sigma. For anti-p11 immunoprecipitation, cell fractionations were
first incubated with anti-p11 antibodies and then with protein A
sepharose beads. All immunoprecipitations were done at 4uC
overnight, followed by washing with Lysis 250 buffer [37].
After whole cell extracts, cell fractions, or immunoprecipitants
were boiled in SDS-sampling buffer, they were loaded on 10%
gradient SDS-PAGE (BioRad). The gel was then transferred to a
nitrocellulose membrane and blotted with the rabbit anti-AnxA2
polyclonal antibody at a 1:1000 dilution followed by HRP-
conjugated goat anti-rabbit IgG (Amershan Pharmacia) at a
1:3000 dilution.
Recombinant His6-tagged ANXA2 was expressed in TOP10 E.
coli and purified on a High-Trap Ni column according to the
manufacturer’s manual (Amershan Pharmacia). One microgram
of purified His6-tagged ANXA2 was loaded on each well of a 10%
gradient SDS-PAGE. After transferring to a nitrocellulose
membrane, each individual lane was blotted with either pre-
vaccination serum or post-vaccination serum at a 1:1000 dilution.
Mouse anti-human IgG antibody (Sigma) was used at a 1:5000
dilution as the secondary antibody.
Total cellular Rho, or activated Rho which was isolated by
incubating the cell extract with an activated Rho affinity binding
column (GST-tagged Rho-binding domain of Rhotekin), were
detected by western blot with mouse anti-Rho A,B,C mAbs
provided by the Rho Activation Assay Kit according to the
manufacturer’s manual (Upstate).
Reverse transcription and real-time PCR
RNA was isolated from cells using the RNAEasy kit (Qiagen),
and reverse transcribed using the first strand cDNA synthesis kit
(Invitrogen). Quantitative real-time reverse transcription-PCR
(qRT-PCR) was performed with gene-specific fluorescent Taq-
Man probes (Applied Biosystems) using an ABI PRISM 7500
Sequence Detection System Instrument and the associated
software (Applied Biosystems) following the manufacturer’s
instructions. Each reaction was performed in triplicate at 2
cDNA dilutions. The standard human b-actin gene (BACT;
Applied Biosystems) was used to normalize variations in the
quantities of input cDNA.
GFP-sorted, shRNA-lentiviral infected cells were subjected to
real-time RT-PCR analysis to measure the mRNA expression of
E-cadherin, slug, and vimentin. As a negative control, the
lentivirus expressing only GFP was also used to infect a control
population of Panc10.05 cells. These cells were also sorted for
GFP-positive cells for this analysis. One pair of Panc10.05 cell
lines, with and without ANXA2 shRNA, were treated with TGFb1
for 48 hours before they were harvested for mRNA expression
analysis.
Mouse models of PDA
All animal experiments conformed to the guidelines of the
Animal Care and Use Committee of the Johns Hopkins University
and animals were maintained in accordance to guidelines of the
American Association of Laboratory Animal Care (Approval#
MO08M142).
The mouse liver metastasis model was established using a
previously described hemispleen injection technique [39,40]. The
transplantable tumor model allows for the assessment of in vivo
tumor growth following shRNA knockdown of targeted PDA
expressed proteins. The spleens of anesthetized female C57Bl/6
mice ages 8 to 10 weeks were divided into two halves and the
halves were clipped. Mouse PDA cells (2610
6) were injected into
the splenic bed (splenic artery and veins) through one hemispleen
followed by a flush with the HBSS buffer. After 30 seconds, the
splenic vessels draining the injected hemispleen was clipped and
the hemispleen was removed. The abdominal wall was sutured,
and the skin adapted using wound clips. All mice were followed
three times a week for survival. At necropsy, mice were examined
macroscopically; and multiple sections of livers and splenic bed
injection sites were examined microscopically with H&E staining
and, as indicated, anti-ANXA2 IHC.
For survival analysis, mice were treated intraperitoneally with
10 mg anti-ANXA2 monoclonal antibody ZO14 antibodies
(Invitrogen) or isotype control IgG1 in 100 ml PBS twice a week
starting the day following the hemisplenectomy procedure and
continued until death. For the analysis of Qtracker-labeled cells,
mice in each group were treated intraperitoneally either with
100 mg anti-ANXA2 monoclonal antibody ZO14 or with 100 mg
isotype control IgG1 on the day following the hemisplenectomy
procedure and sacrificed 5 days later.
Targeting Pancreatic Cancer Metastases via ANXA2
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e19390Statistics
Statistical analysis was performed using software GraphPad
Prism 5. Two tailed Mann-Whitney test was used to compare
differences between treatment groups. Mouse survival was
analyzed by the Kaplan-meier curve and the Log-Rank test.
Mouse experimental data from independent experiments were
shown in a combined analysis because of the consistency of the
results.
Supporting Information
Table S1 Cell Surface Localization of Annexin A2 in
Cells with Different Invasive Capacities.
(PDF)
Figure S1 PDA patients demonstrate vaccine induced
ANXA2-specific serologic responses. A. Purified recombi-
nant His6-tagged ANXA2 (His6-ANXA2) on a SDS-PAGE gel
stained with coommassie blue. B. Purified His6 tagged ANXA2 on
a SDS-PAGE gel was western-blotted by pre- and post-vaccination
sera. Patients marked by * had antibody induction, which was
manifested by stronger signals of ANXA2 on western blot with
post-vaccination versus pre-vaccination sera. C. Pre- and post-
vaccination sera from patients were tested for the presence of anti-
ANXA2 antibodies by ELISA using purified recombinant
ANXA2-coated plates. Positive antibody induction, which was
manifested by a more than 2-fold increase in antibody reaction,
was marked by *.
(TIF)
Figure S2 Cell surface expression of ANXA2 is in-
creased in the majority of human PDAs. The pattern of
ANXA2 expression was analyzed by IHC in 52 of 60 resected
tumors from patients treated in a Phase II study for whom
specimens were available for staining. Representative IHC
staining of ANXA2 in these human PDAs is shown (panels A,
B, C). Cell-surface expression of ANXA2 was semiquantitated
using a score of 0 to 3, with a score of 0 representing no staining
and a score of 3 representing the strongest staining. Normal
pancreatic duct, PanINs and PDA are indicated. Cytoplasmic and
luminal staining was excluded from scoring. Shown is the intensity
of ANXA2 expression on the cell surface. PDA cells vary in their
ANXA2 expression level within the same tumor tissue (panel C).
To account for expression variability within each specimen, the
percentage of PDA cells at each score level was estimated and the
average score of each PDA tissue was calculated by multiplying
each score by their percentages (see Supporting Information
Materials and Methods). As expected, none of the normal
appearing ductal epithelial cells within the resected tumor masses
express 3+ ANXA2 and few express 2+ ANXA2 (panel B). An
average score of 1.5 or above was considered representative of
increased cell surface expression of ANXA2 in the tumor tissue.
(TIF)
Figure S3 ANXA2 shRNA inhibits the invasion capacity
of multiple human and mouse PDA cell lines and PDA
cell invasion potentials vary among different PDA cell
lines and do not correlate with their proliferative rates.
A. Human Panc2.03 PDA cells or mouse Panc02 PDA cells were
infected with lentivirus carrying the shRNA specific for human or
mouse ANXA2 or lentivirus carrying the control shRNA. Invaded
cells were measured by MTT assays and normalized by total cell
numbers. Triplicate experiments were done for control shRNA
and ANXA2 shRNA, respectively. B. Panc10.05 (lanes 1,3) or
Panc02 cells (lanes 2,4) infected with lentivirus either carrying
shRNA specific for human or mouse ANXA2 knockdown (lanes 3
and 4, respectively) or carrying control shRNA (lanes 1,2) were
sorted for GFP-positive cells by FACS with one aliquot of cells
saved for analysis of ANXA2 expression prior to each experiment.
A representative western blot using the rabbit anti-ANXA2
antibody and the rabbit anti-GAPDH antibody (control) is shown.
C. A panel of PDA cell lines derived from primary resected tumors
were evaluated in an in vitro invasion assay. Of 11 PDA cell lines
tested, 8 have higher and 3 have lower invasion capacity (Table
S1). Shown are average MTT units on three parallel experiments
normalized to total cell numbers. D. Expression of ANXA2 in
each PDA cell line demonstrated by immunoblot analyses with
anti-ANXA2 polyclonal antibody. Lanes 1–11 correspond to
human PDA cell lines: Panc01.28, Panc10.05, Panc2.8, Panc2.03,
Panc4.03, PancTS0129, Panc3.11, Panc2.13, Panc6.03,
Panc9.3.96, and Panc2.43, respectively; lane 12, human pancre-
atic para-cancerous fibroblast cells. Expression of ANXA2 is
slightly lower in cells with lower invasion capacity and slightly
higher in those with higher invasion capacity, suggesting that over
expression of ANXA2 in PDAs may contribute to, but does not
entirely explain the range of invasion potential of these PDA cell
lines. E. Growth curves of selected PDA cell lines measured by
MTT assays. Note that Panc3.11 cells with low invasive capacity
grow similarly to Panc10.05 or Panc2.8 with high invasive
capacity.
(TIF)
Figure S4 PDA cell invasion potential correlates with
ANXA2 surface localization on PDA cells and PDA cells
expressing the exogenous ANXA2-Y23A mutant have
reduced surface localization and invasion potential in
vitro.A . Fluorescent immunostaining shows predominant cell
surface localization of ANXA2 in representative cells with higher
invasion capacity (Panc2.43, Panc2.03), but not in cells with lower
invasion capacity (human fibroblast, Panc3.11, Panc9.3.96). See
supplemental Figure 6 for Panc10.05 cells. FITC indicates the
images of immunostaining with rabbit anti-ANXA2 polyclonal
antibody and FITC-conjugated secondary antibody. FITC+DAPI
indicates the overlapped images of FITC staining of ANXA2 and
DAPI staining of nuclei. Fractions of images are enlarged for
better visualization. B. Fluorescent immunostaining of ANXA2 in
Panc10.05 cells either uninfected or infected with lentivirus
expressing wild-type ANXA2, lentivirus expressing Y23A mutated
ANXA2 or lentivirus expressing Y23E mutated ANXA2. FITC
images or overlapped images of FITC and DAPI staining are
shown as indicated. Note that immunostaining of ANXA2
detected both exogenous and endogenous ANXA2. In cells
infected with the tyrosine site loss variant LV-ANXA2
Y23A, even
endogenous ANXA2 no longer localized to the cell surface,
suggesting that ANXA2
Y23A has a dominant negative effect
(Figure S5). C. FLAG-tagged ANXA2 expression in Panc10.05
cells transfected with the pcDNA-based plasmid carrying AN-
XA2
WT-FLAG, the plasmid carrying ANXA2
Y23A-FLAG, or the
plasmid carrying ANXA2
Y23E-FLAG. Membrane fractions (M)
and cytoplasmic fractions (C) were isolated by biochemical
fractionation and blotted with mouse anti-GST antibodies as a
quality control. The result shows that the membrane fractions are
not contaminated by cytoplasmic protein. D. In vitro invasion of
Panc10.05 cells transfected with the pcDNA-based plasmid
carrying ANXA2
WT-FLAG (lane 1) or the plasmid carrying
ANXA2
Y23A-FLAG (lane 2). Results of duplicate experiments are
shown.
(TIF)
Figure S5 The ANXA2-Y23A mutant demonstrates a
dominant negative effect. A. Panc10.05 cells infected with
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lentivirus expressing Y23A mutated ANXA2 (lanes 3–5) were
fractionated into membrane (M, lanes 1,2,4,5) and cytoplasmic
fractions (C, lane 3). The fractions were immunoprecipated by
either rabbit anti-ANXA2 antibodies or mouse anti-p11
antibodies as indicated and immunoblotted with anti-ANXA2
antibodies and anti-p11 antibodies, respectively. Note that
ANXA2 and p11 can be co-immunoprecipated from the
membrane fraction of the cells exogenously expressing
ANXA2-WT and from the cytoplasmic fraction of the cells
exogenously expressing ANXA2-Y23A, suggesting that
ANXA2-Y23A does not affect the complex of ANXA2 and
p11 in the cytosol. However, neither ANXA2 nor p11 can be
detected in the membrane fraction of cells exogenously
expressing ANXA2-Y23A although these cells should still have
endogenous expression of the wild-type ANXA2. Therefore, this
result suggests that exogenous ANXA2-Y23A may have
sequestered p11 in the cytosol. B. Whole cell extracts from
Panc10.05 cells either uninfected (lane 1), infected with
lentivirus expressing wild-type ANXA2 (lane 2), lentivirus
expressing Y23A mutated ANXA2 (lane 3), or lentivirus
expressing Y23E mutated ANXA2 (lane 4), were analyzed by
w e s t e r nb l o tw i t hr a b b i ta n t i - ANXA2 antibodies and mouse
anti-p11 antibodies. This result shows that the total ANXA2
expression is increased in the cells exogenously expressing
ANXA2 as compared with that in the parental cells, whereas the
expression level of p11 remains to be the same. This result
further suggests that cytoplasmic-localized ANXA2-Y23A has
the potential to sequester all the p11 proteins in the cytosol
because it is overexpressed and more abundant than the
endogenous wild-type ANXA2. Therefore, the reason for the
observed dominant negative effect of overexpressed ANXA2-
Y23A is likely due to little p11 being available to bind
endogenous wild-type ANXA2 which depends on p11 for its
translocation [16]. The same experiments were done with
mouse Panc02 cells and similar results were obtained.
(TIF)
Figure S6 Liver metastases model of mouse PDAs.
Schema showing the hemisplenectomy model for establishing
PDA liver metastases. Mouse PDA cells injected into the hemi-
spleen of syngeneic mice form tumors at the splenic bed and
metastases in the liver.
(TIF)
Figure S7 Histological analysis of tumors formed in the
liver metastases model. Shown are representative results of
IHC analysis evaluating ANXA2 expression using polyclonal anti-
ANXA2 antibodies to stain tumors formed at the splenic bed (left
panels) and in the liver (right panels). Upper panels received
control shRNA and lower panels received ANXA2 shRNA. All
panels, 10x amplification. Mice were examined macroscopically;
and multiple sections of livers and splenic bed injection sites were
examined microscopically with H&E staining. All mice in both
groups had tumors at the splenic bed injection site. These tumors
were likely formed by PDA cells left behind during the splenic
injection. Sizes of these tumors were difficult to measure as they
adhered and/or infiltrated the remaining spleen. However, tumors
that formed at the splenic bed in mice of the ANXA2 shRNA group
appeared to be larger and more prominent than those of the
control group. It is possible that the prolonged survival in these
mice allowed continued locoregional growth when compared with
the tumors in the control mice. IHC analyses were performed on
the liver metastases and the locoreginal tumors that formed at the
splenic bed to evaluate ANXA2 expression and localization. As
shown in this figure, PDA cells in tumors excised from the control
mice that formed at the splenic bed (panel a) and that metastasized
to the liver (panel b) stained positive for cell surface ANXA2. In
contrast, the majority of PDA cells expressing ANXA2 shRNA in
tumors that formed at the splenic bed failed to stain for ANXA2
(panel c), consistent with the effect of shRNA. It is not surprising to
see a few ANXA2 positive PDA cells (representatives indicated by
arrows) because RNA interference is not able to knock down gene
expression completely. Panel d, arrow indicates a micro-metastasis
that expresses ANXA2. Of note, 5 of the 17 mice in the ANXA2
shRNA group were found to have microscopic metastases in their
liver on H&E staining. These micro-metastatic tumors stained
positively for cell surface ANXA2, supporting ANXA2 mediated
metastasis formation likely due to the incomplete knockdown of
ANXA2 with shRNA.
(TIF)
Figure S8 Histological analysis of metastases formed in
the orthotopic PDA model. The orthotopic PDA model was
perfomed as previously described [25]. Briefly, 1610
6 mouse PDA
cells were injected s.c. into syngeneic female C57Bl/6 mice. After
2 to 4 weeks, the s.c. tumors were harvested and cut into cubes of
,1m m
3. New syngeneic female C57Bl/6mice, ages 8 to 10
weeks, were anesthetized. The abdomen was opened via a
subcostal left incision of 1 cm. A small pocket was prepared
inside the pancreas using microscissors, into which one piece of the
s.c. tumor was implanted. The incision in the pancreas was closed
with a suture. The abdominal wall was sutured, and the skin
adapted using wound clips. For the first experiment, 5 mice were
implanted with Panc02 tumors infected with control lentivirus and
8 mice with ANXA2 shRNA. On day 25 following implantation,
some mice in the control group were found dead. Therefore,
remaining mice in both groups were euthanized for necropsy. For
the second experiment, an additional 6 mice were implanted with
tumors infected with control lentivirus and 7 mice with ANXA2
shRNA. On day 21 following implantation, all the mice in both
groups were euthanized while they were all still alive. 11/11 mice
in the control group developed severe peritoneal dissemination of
large implants. Although 10/15 mice in the ANXA2 shRNA group
developed peritoneal metastases, they were less extensive, smaller
peritoneal metastases. A. Shown are representative H&E staining
sections of peritoneal metastases, indicated by arrows. Left panels:
control shRNA group; right panels: ANXA2 shRNA group. Left
and right lower panels: enlarged areas of peritoneal metastases. B.
At the time of necropsy, PDAs at the primary implantation site
were measured and did not differ significantly between the two
groups (p=0.248). C. The comparison of the sizes of peritoneal
metastases between the two groups in the second experiment is
shown. The sizes of peritoneal implants differs significantly
between the two groups (p=0.0012). The largest metastasis from
each mouse was chosen for paraffin-embedding and for measure-
ment. Because mice in the ANXA2 group developed very small
peritoneal metastases, all measurements were done on the
microscope-scanned, H&E stained, tissue slides. D. Representative
results of immunohistochemistry analysis with polyclonal anti-
ANXA2 antibodies of tumors formed in the pancreas and
peritoneal metastases are shown. Subpanels (a),(c),(d), 10x
amplification; subpanel (b), 4x amplification. In subpanel (d),
arrow indicates a small peritoneal metastasis. Note that the small
peritoneal tumors from the ANXA2 shRNA group stained positive
for cell surface ANXA2, suggesting that they were formed by cells
that still expressed ANXA2 due to incomplete knockdown by
ANXA2 shRNA.
(TIF)
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